1 published article · Updated continuously
7 trials tracked for Nausea and vomiting: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 450 citations.
Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical evidence supports the use of several pharmacological agents for managing nausea and vomiting. Olanzapine was evaluated in a Phase 3 trial where median nausea scores were reported as low (0 to 1) across study arms, with mean toxicity scores related to the drug remaining low (0.4 to 2.3) 1.
APF530 demonstrated significant efficacy in managing chemotherapy-induced symptoms; patients showed high rates of Complete Response (CR) during both acute (0-24 hours) and delayed-onset (24-120 hours) phases, as well as overall complete control throughout the first course of chemotherapy 2.
Aprepitant was utilized in multiple studies. In one trial, 54 participants achieved no emesis and required no rescue therapy within 5 days of receiving FOLFOX or FOLFIRI 5. Another study evaluating aprepitant for acute vomiting showed a controlled response in 20 participants with only 2 cases of high-grade toxicity (Grade 3, 4, or 5) 7.
Dexamethasone was evaluated as a treatment; however, statistical analysis did not show a significant difference in the percentage of complete responders across different observation windows (p=0.2344 to p=0.3694) 3.
AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
